Acute Respiratory Distress Syndrome Clinical Trial Pipeline Analysis: 40+ Key Companies Shaping the Future of ARDS Therapeutics | DelveInsight

DelveInsight's Acute Respiratory Distress Syndrome (ARDS) Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Acute Respiratory Distress Syndrome (ARDS) therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Acute Respiratory Distress Syndrome (ARDS) pipeline domain.

Key takeaways from the Acute Respiratory Distress Syndrome (ARDS) Clinical Trial Landscape Report
• DelveInsight's Acute Respiratory Distress Syndrome (ARDS) pipeline report depicts a robust space with 40+ active players working to develop 40+ pipeline therapies for Acute Respiratory Distress Syndrome (ARDS) treatment.
• Key Acute Respiratory Distress Syndrome (ARDS) companies such as Athersys, Inc., Faron Pharmaceuticals, Windtree Therapeutics, BioAegis Therapeutics, Direct Biologics, BrainStorm Cell Therapeutics, and others
• Promising Acute Respiratory Distress Syndrome (ARDS) pipeline therapies in various stages of development include MultiStem (invimestrocel), Traumakine (interferon beta-1a), Aerosurf, and others

Request a sample and discover the recent advances in Acute Respiratory Distress Syndrome (ARDS) treatment drugs https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

What is Acute Respiratory Distress Syndrome (ARDS)?
Acute Respiratory Distress Syndrome (ARDS) is a rare form of severe respiratory condition that originates in the lungs due to acute inflammation and injury. It is characterized by lung damage such as fluid accumulation in alveoli and may lead to respiratory failure and multi-organ complications as the disease progresses. The symptoms include shortness of breath, hypoxemia, rapid breathing, and respiratory distress. The treatment involves supportive care and mechanical ventilation. The causes are associated with infections, trauma, and systemic inflammation. The diagnosis is based on clinical examination, imaging, blood tests, and oxygenation assessment.

Emerging Acute Respiratory Distress Syndrome (ARDS) Drug Profiles

MultiStem: Athersys, Inc.
MultiStem (invimestrocel) is an innovative cell therapy that uses multipotent adult progenitor cells for therapeutic action. Its active component is designed to modulate immune response and reduce inflammation in lung tissue, where it is administered intravenously and evaluated in clinical trials for Acute Respiratory Distress Syndrome (ARDS). The therapy has received Fast Track designation in the United States for its development in Acute Respiratory Distress Syndrome (ARDS).

Traumakine: Faron Pharmaceuticals
Traumakine (interferon beta-1a) is a recombinant protein therapy being developed for multiple respiratory indications, including Acute Respiratory Distress Syndrome (ARDS). It targets endothelial stabilization and is administered intravenously. The therapy is currently in Phase II/III clinical development and is being evaluated for its role in treating Acute Respiratory Distress Syndrome (ARDS).

Learn more about the novel and emerging Acute Respiratory Distress Syndrome (ARDS) pipeline therapies at: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Recent Developments in the Acute Respiratory Distress Syndrome (ARDS) Clinical Trial Landscape
• In March 2026, Athersys, Inc., announced that findings from recent supportive trials with MultiStem (invimestrocel) in the treatment of Acute Respiratory Distress Syndrome (ARDS) are being presented at scientific meetings focused on respiratory diseases.
• In February 2025, Faron Pharmaceuticals announced that the US Food and Drug Administration (FDA) had granted regulatory support to Traumakine (interferon beta-1a) for the treatment of Acute Respiratory Distress Syndrome (ARDS), after prior clinical evaluations.
• In April 2026, Windtree Therapeutics reported continued clinical progress of Aerosurf in patients with Acute Respiratory Distress Syndrome (ARDS), highlighting encouraging efficacy signals in ongoing studies.
• In March 2026, Direct Biologics announced ongoing clinical development activities for its Acute Respiratory Distress Syndrome (ARDS) pipeline candidates, focusing on advancing targeted therapies across early and mid-stage trials.
• In February 2026, BioAegis Therapeutics provided updates on pipeline candidates, indicating continued enrollment and evaluation in Phase I clinical trials for Acute Respiratory Distress Syndrome (ARDS).

Scope of the Acute Respiratory Distress Syndrome (ARDS) Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Inhalation
• Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Polymer, Peptide, Gene Therapy
• Key Acute Respiratory Distress Syndrome (ARDS) Companies: Athersys, Inc., Faron Pharmaceuticals, Windtree Therapeutics, BioAegis Therapeutics, Direct Biologics, BrainStorm Cell Therapeutics, and others
• Key Acute Respiratory Distress Syndrome (ARDS) Pipeline Therapies: MultiStem (invimestrocel), Traumakine (interferon beta-1a), Aerosurf, and others

Dive deep into rich insights for new drugs for Acute Respiratory Distress Syndrome (ARDS) treatment, visit https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents
1. Acute Respiratory Distress Syndrome (ARDS) Pipeline Report Introduction
2. Acute Respiratory Distress Syndrome (ARDS) Pipeline Report Executive Summary
3. Acute Respiratory Distress Syndrome (ARDS) Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Acute Respiratory Distress Syndrome (ARDS) Pipeline Therapeutics
6. Acute Respiratory Distress Syndrome (ARDS) Pipeline: Late Stage Products (Pre-registration)
7. Acute Respiratory Distress Syndrome (ARDS) Pipeline: Late Stage Products (Phase III)
8. Acute Respiratory Distress Syndrome (ARDS) Pipeline: Mid Stage Products (Phase II)
9. Acute Respiratory Distress Syndrome (ARDS) Pipeline: Early Stage Products (Phase I)
10. Acute Respiratory Distress Syndrome (ARDS) Pipeline Therapeutics Assessment
11. Inactive Products in the Acute Respiratory Distress Syndrome (ARDS) Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products in the Acute Respiratory Distress Syndrome (ARDS) Pipeline
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the Acute Respiratory Distress Syndrome (ARDS) pipeline therapeutics, reach out at: https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-ards-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kspr

Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.